Search Results

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

• Source: An Open-Label, Single-Dose Clinical Study to Evaluate Pharmacokinetics of MK-8507 in Participants With Mild or Moderate Hepatic Impairment.

Record details

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

• Source: A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With

Record details

A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)

• Source: An Open-Label Study to Assess the Two-Way Interaction Between Multiple Weekly Doses of MK-8507 and Single Doses of Islatravir (MK-8591) in Healthy Adult Participants

Record details

Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

• Source: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected PatientsSchurmann D, Jackson Rudd D,

Record details

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

• Authors : Martin Daumer; Wendy Ankrom; Deanne Jackson Rudd

Subjects: Adult; Combination therapy; Adolescent

• Source: Journal of Acquired Immune Deficiency Syndromes (1999)

Record details

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

• Authors : Andrea K. Schaeffer; Deborah Panebianco; Charles Tomek

Subjects: Adult; medicine.medical_specialty; HIV Infections

• Source: Antimicrobial Agents and Chemotherapy

Record details

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor

• Authors : Gillespie, Gillian; Jackson Rudd, Deanne; Zhang, Saijuan

• Source: The Journal of Clinical Pharmacology ; volume 62, issue 2, page 199-205 ; ISSN 0091-2700 1552-4604

Record details

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

• Authors : Schürmann, Dirk; Jackson Rudd, Deanne; Schaeffer, Andrea

• Source: JAIDS Journal of Acquired Immune Deficiency Syndromes ; volume 89, issue 2, page 191-198 ; ISSN 1525-4135

Record details

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

• Authors : Ankrom, Wendy; Jackson Rudd, Deanne; Schaeffer, Andrea ...

• Source: Antimicrobial Agents and Chemotherapy ; volume 65, issue 12 ; ISSN 0066-4804 1098-6596

Record details

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK-8507, an Investigational, Oral, Once-Weekly Nonnucleoside Reverse Transcriptase Inhibitor

• Authors : Deanne Jackson Rudd; Charles Tomek; S. Aubrey Stoch

Subjects: Adult; Male; HIV Infections

• Source: Journal of clinical pharmacology. 62(2)

Record details